41 Supported by research
Supplementing with omega-3 plus vitamin D slowed epigenetic aging by about 3.3 months.
"So, when you looked at omega-3 plus vitamin D, it slowed epigenetic aging even further than just omega-3 alone. It slowed it by about 3.3 months." (said at 0:00:14)
A post hoc analysis of 777 older adults from the randomized controlled DO-HEALTH trial investigated the individual and combined effects of vitamin D (2,000 IU/day), omega-3 (1 g/day), and a home exercise program on DNA methylation (DNAm) measures of biological aging over 3 years. The researchers found that omega-3 alone slowed several epigenetic aging clocks (PhenoAge, GrimAge2, and DunedinPACE) and demonstrated additive protective benefits when combined with vitamin D and exercise (specifically for PhenoAge), with effect sizes corresponding to an attenuation of biological aging by approximately 2.9 to 3.8 months (around 3.3 months on average). Certainty is moderate because the findings stem from a post hoc secondary analysis of trial data.
- supports: Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation cloc… (Nature aging 2025) · cited 126x in the literature
"Omega-3 alone slowed the DNAm clocks PhenoAge, GrimAge2 and DunedinPACE, and all three treatments had additive benefits on PhenoAge. Overall, from baseline to year 3, standardized effects ranged from 0.16 to 0.32 units (2.9-3.8 months). In summary, our trial indicates a small protective effect of omega-3 treatment on slowing biological aging over 3 years across several clocks, with an additive protective effect of omega-3, vitamin D and exercise based on PhenoAge." (abstract, results, passage verified)
pubmedfull study (doi)
Combining resistance training, omega-3, and vitamin D slowed epigenetic aging by about 3.8 months.
"When you looked at all three combined, resistance training, omega-3, and vitamin D, it slowed it by about 3.8 months." (said at 0:00:30)
A post hoc randomized controlled trial analysis of 777 participants in the DO-HEALTH trial examined the individual and combined effects of vitamin D (2,000 IU/day), omega-3 fatty acids (1 g/day), and a simple home exercise program over 3 years. The researchers observed additive benefits across the three interventions on DNA methylation biological aging (specifically the PhenoAge clock), with standardized slowing effects across measures ranging from 2.9 to 3.8 months over the 3-year follow-up.
- supports: Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation cloc… (Nature aging 2025) · cited 126x in the literature
"Omega-3 alone slowed the DNAm clocks PhenoAge, GrimAge2 and DunedinPACE, and all three treatments had additive benefits on PhenoAge. Overall, from baseline to year 3, standardized effects ranged from 0.16 to 0.32 units (2.9-3.8 months). In summary, our trial indicates a small protective effect of omega-3 treatment on slowing biological aging over 3 years across several clocks, with an additive protective effect of omega-3, vitamin D and exercise based on PhenoAge." (abstract, results, passage verified)
pubmedfull study (doi)
About 90% of the US population does not consume enough seafood.
"So, about 90% of the US population does not eat enough seafood" (said at 0:04:02)
According to the Dietary Guidelines for Americans and analyses of the National Health and Nutrition Examination Survey (NHANES), approximately 90% of the US population fails to meet the recommended seafood intake of at least 8 ounces per week. Nationally representative dietary intake data consistently show that mean adult seafood consumption (averaging roughly 120 to 142 g/week, or ~4.2 to 5.0 oz/week) falls well below federal dietary recommendations, with more than 90–95% of various demographic subgroups not meeting recommended seafood or marine omega-3 (EPA/DHA) targets.
Globally, about 80% of the population does not get enough omega-3 from their diet.
"and about 80% globally of the population not getting enough omega-3 from their diet." (said at 0:04:05)
A systematic analysis of dietary surveys representing 113 countries and 82% of the global adult population (the 2010 Global Burden of Diseases Nutrition and Chronic Diseases Expert Group) estimated that countries representing only 18.9% of the world's population met the recommended optimal intake for seafood omega-3 fatty acids (≥250 mg/day of EPA/DHA), meaning roughly 81% of the global population fell below target dietary intakes. Global biomarker mapping studies likewise show that the vast majority of countries have low to very low blood levels of EPA and DHA (Omega-3 Index ≤ 6%).
- supports: Global, regional, and national consumption levels of dietary fats and oils in 1990 and 201… (BMJ (Clinical research ed.) 2014) · cited 576x in the literature
"Countries representing 52.4% of the global population had national mean intakes for omega 6 fat ≥ 5%E; corresponding proportions meeting optimal intakes were 0.6% for trans fat (≤ 0.5%E); 87.6% for dietary cholesterol (<300 mg/day); 18.9% for seafood omega 3 fat (≥ 250 mg/day); and 43.9% for plant omega 3 fat (≥ 1,100 mg/day)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Omega-3 world map: 2024 update. (Progress in lipid research 2024) · cited 89x in the literature
"Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low." (abstract, results, passage verified)
pubmedfull study (doi)
A study from Harvard identified low omega-3 intake as one of the top six preventable causes of death.
"Which leads me to this really important study that was published out of Harvard several ye— several years ago that identified low omega-3 intake as one of the top six preventable causes of death." (said at 0:04:08)
A landmark 2009 comparative risk assessment study led by researchers at the Harvard School of Public Health (Danaei et al., published in PLoS Medicine) analyzed 12 modifiable dietary, lifestyle, and metabolic risk factors for mortality in the United States. The authors estimated that low dietary intake of omega-3 fatty acids accounted for approximately 84,000 preventable deaths annually (95% CI: 72,000–96,000), ranking as the sixth leading preventable cause of death overall (following tobacco smoking, high blood pressure, overweight-obesity, high blood glucose, and physical inactivity) and among the leading dietary risk factors alongside high salt intake.
- supports: The preventable causes of death in the United States: comparative risk assessment of dieta… (PLoS medicine 2009) · cited 2894x in the literature
"High dietary salt (102,000; 97,000-107,000), low dietary omega-3 fatty acids (84,000; 72,000-96,000), and high dietary trans fatty acids (82,000; 63,000-97,000) were the dietary risks with the largest mortality effects." (abstract, results, passage verified)
pubmedfull study (doi)
In the United States, 84,000 deaths per year are attributed to insufficient dietary intake of omega-3 fatty acids.
"It was actually found that 84,000 deaths a year were attributed to people not getting enough omega-3, and by people I mean in the United States were not getting enough omega-3 from their diet." (said at 0:05:28)
A landmark comparative risk assessment study by Danaei and colleagues (2009) evaluated preventable causes of death in the United States using national health survey data, mortality statistics, and effect sizes from meta-analyses. The authors estimated that low dietary intake of omega-3 fatty acids (seafood) accounted for approximately 84,000 deaths per year (95% CI: 72,000–96,000) in US adults, making it one of the leading dietary risk factors for preventable mortality.
- supports: The preventable causes of death in the United States: comparative risk assessment of dieta… (PLoS medicine 2009) · cited 2894x in the literature
"High dietary salt (102,000; 97,000-107,000), low dietary omega-3 fatty acids (84,000; 72,000-96,000), and high dietary trans fatty acids (82,000; 63,000-97,000) were the dietary risks with the largest mortality effects." (abstract, results, passage verified)
pubmedfull study (doi)
Trans fat consumption is attributed to 82,000 deaths per year in the United States.
"Um it leads to cardiovascular disease, and that was attributed to 82,000 deaths per year." (said at 0:05:45)
A landmark comparative risk assessment study by Danaei et al. (2009) evaluating preventable causes of death in the United States estimated that high dietary trans fatty acid intake was responsible for approximately 82,000 deaths per year (95% CI: 63,000–97,000) in US adults, primarily driven by cardiovascular disease mortality.
- supports: The preventable causes of death in the United States: comparative risk assessment of dieta… (PLoS medicine 2009) · cited 2894x in the literature
"High dietary salt (102,000; 97,000-107,000), low dietary omega-3 fatty acids (84,000; 72,000-96,000), and high dietary trans fatty acids (82,000; 63,000-97,000) were the dietary risks with the largest mortality effects." (abstract, results, passage verified)
pubmedfull study (doi)
People with an omega-3 index of 8% or higher had a 90% lower risk of sudden cardiac death compared to those with an index of 4% or below.
"what they found was that those people with a high omega-3 index, that's indicated as 8% or more, so 8% of the fatty acids in the cell— in the red blood cell membranes were composed of these omega-3 fatty acids, um they had a 90% lower risk of sudden cardiac death compared to people with a low omega-3 index being 4% or below." (said at 0:07:11)
The original proposal and validation of the Omega-3 Index (the sum of EPA and DHA expressed as a percentage of total fatty acids in red blood cell membranes) by Harris and von Schacky defined high-risk (<4%), intermediate-risk (4–8%), and low-risk (>8%) cardioprotective zones. Based on re-evaluations of prospective epidemiological cohorts such as the Physicians' Health Study, individuals with the highest omega-3 levels (corresponding to an Omega-3 Index of ≥8%) experienced an approximate 90% reduction in the risk of sudden cardiac death (relative risk ~0.10) compared to those in the lowest category (corresponding to ≤4%).
- supports: The Omega-3 Index: a new risk factor for death from coronary heart disease? (Preventive medicine 2004) · cited 1109x in the literature
"An Omega-3 Index of > or = 8% was associated with the greatest cardioprotection, whereas an index of < or = 4% was associated with the least." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Cardiovascular risk and the omega-3 index. (Journal of cardiovascular medicine (Hagerstown, Md.) 2007) · cited 46x in the literature
"Several lines of evidence support the omega-3 index as a risk factor for SCD: in epidemiological studies, a steep dependence of risk for SCD and the omega-3 index has been observed between 6.5% (risk 0.1) and 3.3% (risk 1.0)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The omega-3 index as a risk factor for coronary heart disease. (The American journal of clinical nutrition 2008) · cited 295x in the literature
"Proposed omega-3 index risk zones are (in percentages of erythrocyte FAs): high risk, <4%; intermediate risk, 4-8%; and low risk, >8%." (abstract, passage verified)
pubmedfull study (doi)
In the Framingham cohort, individuals with an omega-3 index of 8% or higher had a 5-year increased life expectancy compared to those with an index of 4% or lower.
"Those individuals with a high omega-3 index of 8% or higher had a 5-year increased life expectancy compared to people with a low omega-3 index of 4% or lower." (said at 0:08:14)
In the Framingham Offspring Cohort, prospective observational analyses led by Harris, McBurney, and colleagues examined the association between the red blood cell Omega-3 Index (O3I) and all-cause mortality. In their 2021 predictive modeling paper (PMID 34134132), red blood cell fatty acid profiles (including high vs. low omega-3 status) predicted all-cause mortality with an effect size comparable to smoking status, corresponding to an estimated ~4.7- to 5-year difference in remaining life expectancy between individuals with an O3I of ~8% versus ~4%. Observational cohort analyses in this population (PMID 29559306) similarly showed that individuals in the highest quintile of O3I had a 34% lower risk of all-cause mortality compared to those in the lowest quintile. Because this finding is derived from prospective observational modeling rather than randomized interventional trials, certainty is graded as low.
The average omega-3 index in Japan is 10%, while in the United States it is about 5%.
"in Japan, their average omega-3 index is 10%. So they're in that high omega-3 index range. In the United States, our omega-3 index on average is about 5%." (said at 0:08:35)
Cross-sectional and observational analyses comparing red blood cell fatty acid levels across populations confirm that the average Omega-3 Index in Japan is in the high/desirable range (>8%, typically around 8–10%), whereas in the United States, the average population Omega-3 Index falls into the low range (>4% to 6%, averaging around 5%).
- supports: Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. (Prostaglandins, leukotrienes, and essential fatty acids 2022) · cited 57x in the literature
"The mean Omega-3 Index of each country was categorized as desirable (>8%), moderate (>6% to 8%), low (>4% to 6%), or very low (≤4%). Only cohorts from Alaska (treated separately from the US), South Korea and Japan showed a desirable Omega-3 Index. The Spanish cohort had a moderate Omega-3 Index, while cohorts from the US, Canada, Italy, and Germany were all classified as low." (abstract, results, passage verified)
pubmedfull study (doi)
People in Japan have a 5-year increased life expectancy compared to people in the United States.
"And if you look at the difference in life expectancy between people that are in the United States versus people that live in Japan, it's about 5-year difference. So people in Japan have a 5-year increased life expectancy compared to people in the United States from that same Framingham cohort." (said at 0:08:50)
Comprehensive global demographic analyses and vital statistics confirm that life expectancy at birth in Japan is approximately 5 to 6 years longer than in the United States. In contemporary global burden of disease and national demographic assessments, Japanese life expectancy consistently ranks among the highest in the world (around 84–85 years), compared to approximately 77–79 years in the United States.
In Framingham study analysis, smokers with a high omega-3 index had the same life expectancy as non-smokers with a low omega-3 index.
"But what's so fascinating is that when you take the smokers that actually have a high omega-3 index, they have the exact same life expectancy as the non-smokers with a low omega-3 index." (said at 0:10:48)
In a 2021 analysis of 2,240 participants from the Framingham Offspring Cohort followed for 11 years (McBurney et al., 2021), researchers evaluated erythrocyte fatty acid patterns, including the Omega-3 Index (O3I), alongside traditional cardiovascular risk factors for predicting all-cause mortality. In their survival and risk modeling, a low Omega-3 Index was associated with a loss in life expectancy comparable to that of smoking (~4.7 years), such that smokers with a high Omega-3 Index and non-smokers with a low Omega-3 Index had nearly identical predicted survival trajectories. As this is observational cohort data, it demonstrates strong statistical association rather than direct randomized causation.
In the REDUCE-IT trial, participants taking 4 grams of Vascepa per day had approximately a 25% lower risk of cardiovascular events, death, and ischemic events over 5 years.
"And what was found was that the people that were given this Vascepa, this high-dose EPA—and it was 4 grams—they actually had about a 25% lower risk of all sorts of cardiovascular events, death, ischemic events." (said at 0:12:49)
In the REDUCE-IT trial (8,179 statin-treated patients followed for a median of 4.9 years), taking 4 grams daily of icosapent ethyl (Vascepa, a purified eicosapentaenoic acid ethyl ester) resulted in a 25% relative reduction in the primary composite cardiovascular outcome compared to placebo (17.2% vs 22.0%, HR 0.75; 95% CI, 0.68 to 0.83; P<0.001). The key secondary composite end point was reduced by 26% (HR 0.74), and cardiovascular death was significantly reduced (HR 0.80).
- supports: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. (The New England journal of medicine 2019) · cited 3309x in the literature
"The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo... A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001)." (abstract, methods and results)
pubmedfull study (doi)
In the VITAL study, taking 840 mg of Lovaza daily led to a 28% lower risk of heart attacks and a 17% lower risk of coronary artery disease compared to placebo.
"So individuals that were given the prescription Lovaza had a 28% lower heart attack risk and they had a 17% lower coronary artery disease risk compared to those given a placebo." (said at 0:13:52)
In the VITAL trial (PMID 30415637), 25,871 participants were randomized to receive 1 g daily of marine omega-3 fatty acids (Omacor/Lovaza, containing 840 mg of EPA and DHA) or placebo. While the primary composite endpoint of major cardiovascular events did not show a statistically significant reduction (hazard ratio [HR] 0.92, 95% CI 0.80 to 1.06), secondary endpoint analyses demonstrated a statistically significant 28% reduction in total myocardial infarction (HR 0.72, 95% CI 0.59 to 0.90) and a 17% reduction in total coronary heart disease (HR 0.83, 95% CI 0.71 to 0.97).
- supports: Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. (The New England journal of medicine 2019) · cited 978x in the literature
"In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21)" (abstract, results, passage verified)
pubmedfull study (doi)
In a Swiss trial, combining omega-3, vitamin D, and strength training reduced pre-frailty by 40% and reduced invasive cancer incidence by 61%.
"So the 3.8 months of epigenetic aging slowing, that was the combined omega-3, vitamin D, and strength training that also reduced pre-frailty by 40%. So even though it was only about a 4-month slowing of epigenetic aging, it reduced frailty by 40%. And it reduced invasive cancer by 61%." (said at 0:24:31)
In the DO-HEALTH trial (a multicenter randomized controlled trial led by researchers in Switzerland evaluating 2,157 community-dwelling adults aged 70 and older), the combination of 2,000 IU/day vitamin D3, 1 g/day marine omega-3s, and a simple home strength exercise program (SHEP) significantly reduced both the odds of becoming pre-frail by approximately 39% (OR 0.61, 95% CI 0.38–0.98) among robust participants and the risk of invasive cancer by 61% (adjusted HR 0.39, 95% CI 0.18–0.85) over 3 years. The certainty is rated moderate due to these being secondary/exploratory outcomes with a relatively small total number of cancer cases.
- supports: Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Can… (Frontiers in aging 2022) · cited 31x in the literature
"For all three treatments combined, the adjusted HR was 0.39 (0.18-0.85; 4 vs. 12 cases). Conclusion: Supplementation with daily high-dose vitamin D 3 plus omega-3s, combined with SHEP, showed cumulative reduction in the cancer risk in generally healthy and active and largely vitamin D-replete adults ≥70 years." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre… (The Journal of frailty & aging 2023) · cited 42x in the literature
"However, the three treatments combined showed significantly decreased odds (OR 0.61 [95% CI 0.38-0.98; p=0.04) of becoming pre-frail compared to control. None of the individual treatments or their combination significantly reduced the odds of becoming frail." (abstract, results, passage verified)
pubmedfull study (doi)
A Japanese study of centenarians, semi-supercentenarians, and supercentenarians found that suppressing inflammation was the only biomarker that predicted reaching the next advanced age milestone and cognitive retention.
"And the only thing that was able to predict whether or not someone was going to go from being an older adult to someone that lives to be 100 and someone that lives to be 100 to 105 and so on was suppressing inflammation. Nothing else predicted it. Not low blood glucose, not lipids, not kidney function, liver function. Nothing else predicted it except for the ability to suppress inflammation." (said at 0:28:11)
A 2015 longitudinal study by Arai et al. combining three Japanese prospective cohorts (1,554 participants, including 684 centenarians and semi-supercentenarians) examined biomarker domain z-scores for inflammation, haematopoiesis, lipid and glucose metabolism, liver function, renal function, and cellular senescence. In multivariate models, systemic inflammation was the sole domain that consistently predicted all-cause mortality across the very old and (semi-)supercentenarians, and it was the primary biomarker predicting cognitive function and physical capability at extreme old age, whereas markers of metabolism, organ function, and telomere length did not.
- supports: Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Lo… (EBioMedicine 2015) · cited 332x in the literature
"We combined z scores from multiple biomarkers to describe haematopoiesis, inflammation, lipid and glucose metabolism, liver function, renal function, and cellular senescence domains. In Cox proportional hazard models, inflammation predicted all-cause mortality with hazard ratios (95% CI) 1.89 (1.21 to 2.95) and 1.36 (1.05 to 1.78) in the very old and (semi-)supercentenarians, respectively. In linear forward stepwise models, inflammation predicted capability (10.8% variance explained) and cognition (8(.)6% variance explained) in (semi-)supercentenarians better than chronologic age or gender." (abstract, results, passage verified)
pubmedfull study (doi)
In the Framingham cohort, individuals with a high omega-3 index had approximately a 50% reduced risk of Alzheimer's disease compared to those with a low index.
"And so again, what Bill found is that individuals that had a high omega-3 index had about a 50% reduced risk of Alzheimer's disease compared to people with a low omega-3 index." (said at 0:29:35)
In an analysis of 1,490 dementia-free participants aged 65 and older from the Framingham Offspring Cohort (co-authored by William S. Harris), participants in the highest quintile of red blood cell (RBC) docosahexaenoic acid (DHA) had a 49% lower risk of incident Alzheimer's disease compared to those in the lowest quintile (hazard ratio 0.51, 95% CI 0.27–0.96) over a median follow-up of 7.2 years. Because this is prospective observational data, the evidence certainty is low.
In the United States, someone has a heart attack approximately every 30 seconds.
"And if you think about heart attacks, I mean, every 30 seconds, somebody in the United States is having a heart attack." (said at 0:07:43)
The host's statement that someone in the United States has a heart attack approximately every 30 seconds is well supported by national epidemiological data. According to statistics published by the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC), an American experiences a coronary event approximately every 25 to 40 seconds, amounting to roughly 800,000 to 1.25 million new and recurrent heart attacks annually in the U.S. population.
Human red blood cells have an average lifespan and turnover time of approximately 120 days.
"So, it's a long-term marker because your red blood cells take about 120 days to turn over." (said at 0:06:41)
Human red blood cells (erythrocytes) have a well-established average circulatory lifespan of approximately 115 to 120 days under normal physiological conditions, which dictates the rate of red blood cell pool renewal and turnover.
- supports: On the Mechanism of Human Red Blood Cell Longevity: Roles of Calcium, the Sodium Pump, PIE… (Frontiers in physiology 2017) · cited 103x in the literature
"In a healthy adult, the transport of O 2 and CO 2 between lungs and tissues is performed by about 2 · 10 13 red blood cells, of which around 1.7 · 10 11 are renewed every day, a turnover resulting from an average circulatory lifespan of about 120 days." (abstract, passage verified)
pubmedfull study (doi) - supports: Exercise, training and red blood cell turnover. (Sports medicine (Auckland, N.Z.) 1995) · cited 201x in the literature
"Although under normal conditions, red blood cells (RBCs) have a lifespan of about 120 days, the rate of aging may increase during intensive training." (abstract, passage verified)
pubmedfull study (doi)
EPA is metabolized into E-series resolvins, while DHA is metabolized into D-series resolvins, protectins, and neuroprotectins.
"So both EPA and DHA, they get metabolized and their metabolites help resolve inflammation. So if we're looking at EPA, they make resolvins, the E series of resolvins. DHA makes the D series, but it also makes the protectins and the neuroprotectins." (said at 0:16:21)
The speaker's statement accurately describes the established biochemical pathways of specialized pro-resolving lipid mediators (SPMs). Eicosapentaenoic acid (EPA) is enzymatically converted into E-series resolvins (such as RvE1–RvE4), whereas docosahexaenoic acid (DHA) is enzymatically converted into D-series resolvins (RvD1–RvD6), protectins (such as protectin D1/PD1), neuroprotectins (the designation for protectins biosynthesized in neural tissues), and maresins, all of which mediate the active resolution of inflammation.
- supports: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their … (Lipids 2004) · cited 346x in the literature
"Compounds derived from EPA carrying potent biological actions (i.e., 1-10 nM range) are designated E series and denoted resolvins of the E series (resolvin E1 or RvE1), and those biosynthesized from the precursor DHA are denoted resolvins of the D series (resolvin D1 or RvD1)." (abstract, review text, passage verified)
pubmedfull study (doi) - supports: Protectins and maresins: New pro-resolving families of mediators in acute inflammation and… (Biochimica et biophysica acta 2015) · cited 500x in the literature
"Given their potent and stereoselective picogram actions, specific members of these new families of mediators from the DHA metabolome were named D-series resolvins (Resolvin D1 to Resolvin D6), protectins (including protectin D1-neuroprotectin D1), and maresins (MaR1 and MaR2)." (abstract, review text, passage verified)
pubmedfull study (doi) - supports: E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of special… (Seminars in immunology 2022) · cited 88x in the literature
"The SPMs biosynthesized from the major omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are coined Resolvins (resolution phase interaction products; E series and D-series), Protectins and Maresins (macrophage mediators in resolving inflammation)... Herein, we review the biosynthesis and functions of the E-series resolvins, namely resolvin E1 (the first n-3 resolvin identified), resolvin E2, resolvin E3 and resolvin E4 biosynthesized from their precursor eicosapentaenoic acid (EPA)" (abstract, review text, passage verified)
pubmedfull study (doi)
The STRENGTH trial testing 4 grams daily of omega-3 carboxylic acids (Epanova) was stopped early due to lack of clinical cardiovascular benefit.
"There's also the STRENGTH trial. This was 4 grams of EPA and DHA. This was Epanova... So that trial was actually ended early because it wasn't really showing any positive results." (said at 0:14:22)
The STRENGTH randomized controlled trial evaluated 4 g/day of omega-3 carboxylic acid (Epanova, containing EPA and DHA) versus corn oil in 13,078 statin-treated patients at high cardiovascular risk. The trial was prematurely halted following an interim analysis showing a low probability of clinical benefit. At trial completion, major adverse cardiovascular events occurred in 12.0% of the omega-3 group versus 12.2% of the corn oil group (hazard ratio 0.99, P = 0.84), showing no significant cardiovascular benefit.
Every 100-milligram-per-day increase in omega-3 fatty acid intake is associated with a 10% lower risk of Alzheimer's disease and cognitive decline.
"So for every increase in, so 100-milligram-per-day increase in omega-3 fatty acids, that was associated with lowering the risk of Alzheimer's disease and cognitive decline by 10%. So as you kept going up 100 milligrams more, you had a 10% lower risk of Alzheimer's disease." (said at 0:31:19)
A 2023 dose-response meta-analysis of prospective cohort studies evaluated the longitudinal relationship between omega-3 fatty acid intake and cognitive outcomes. The authors reported that each 0.1 g/day (100 mg/day) increment of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) intake was linearly associated with an 8% to 9.9% lower risk of cognitive decline. Because these findings are derived primarily from prospective observational cohorts rather than randomized controlled trials, the certainty of evidence for a causal risk reduction is moderate.
Beginning around age 65, the human brain naturally loses 1% to 2% of hippocampal volume per year.
"So as we reach older adulthood, and I mean the age of about 65, we start to lose 1 to 2% of our hippocampus per year. So our brain our hippocampus our brain is atrophying, and specifically our hippocampus is atrophying." (said at 0:32:20)
Published neuroimaging and intervention literature in older adults indicates that the hippocampus naturally undergoes volume loss in late adulthood at an estimated rate of approximately 1% to 2% annually in healthy aging.
A higher omega-3 index is dose-dependently associated with larger hippocampal brain volume in older adults.
"So there are studies that have found that a higher omega-3 index is associated with larger hippocampal brain volume. And um and that was also something that was found to be dose dose-dependent as well." (said at 0:32:48)
Published cohort studies have found that a higher red blood cell omega-3 index (EPA + DHA) is associated with larger hippocampal volume in a continuous (dose-dependent) manner. In the Women's Health Initiative Memory Study (WHIMS-MRI, n=1,111 postmenopausal women), each 1 standard deviation increase in omega-3 index was correlated with a 50 mm³ larger hippocampal volume measured 8 years later (p = 0.036), with participants in the highest quartile having 159 mm³ larger hippocampal volume than those in the lowest quartile. Similarly, in the Framingham Heart Study cohort (n=2,183), higher omega-3 index was linearly associated with larger hippocampal volume (p = 0.013). Because these findings derive from observational cohort designs, the certainty of evidence is low.
In mice, omega-3 deficiency makes cell membranes too stiff, impairing glucose transporters into the brain and leading to the accumulation of tau tangles.
"there's studies that have shown if, for example, you take animals like mice and you make them omega-3 deficient, their glucose transporters aren't functioning right because they're structurally like the membrane's too stiff and so the transporter is not right and so glucose can't get into the brain... It also leads to the accumulation of tau tangles." (said at 0:35:50)
Preclinical animal research supports the claim. Rodent studies demonstrate that dietary omega-3 (n-3) polyunsaturated fatty acid deficiency alters cell membrane phospholipid composition (depleting docosahexaenoic acid, DHA), resulting in reduced expression and impaired activity of glucose transporters (notably GLUT1) at the blood-brain barrier and decreased cerebral glucose uptake. Additionally, studies in transgenic mouse models of Alzheimer's disease (such as 3xTg-AD mice) show that omega-3 deficiency exacerbates or DHA supplementation diminishes the accumulation and hyperphosphorylation of tau pathology and amyloid-beta. Because the direct causal mechanism connecting membrane fluidity changes, glucose hypometabolism, and tau tangle accumulation is supported exclusively by animal models, the GRADE certainty is very low.
- supports: (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the… (The Journal of nutrition 2005) · cited 114x in the literature
"The microvessels and cortex of rats fed the (n-3) PUFA-deficient diet had 50% of the control 22:6(n-3) contents; 22:6(n-3) was replaced by 22:5(n-6). The 55-kDa GLUT1 immunoreactivity in (n-3) PUFA-deficient microvessels was decreased (down 25%, P < 0.01), as was the 45 kDa-GLUT1 in the homogenate (down 30%, P < 0.01)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pat… (The Journal of neuroscience : the official journal of the Society for Neuroscience 2007) · cited 322x in the literature
"Here we show that dietary supplementation with docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, in the 3xTg-AD mouse model of AD reduced the intraneuronal accumulation of both amyloid-beta (Abeta) and tau." (abstract, results, passage verified)
pubmedfull study (doi) - supports: n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain b… (Prostaglandins, leukotrienes, and essential fatty acids 2007) · cited 79x in the literature
"Western immunoblotting analysis showed that endothelial GLUT1 significantly decreased (-23%) in the n-3 PUFA-deficient microvessels compared to control ones, whereas it increased (+35%) in the microvessels of rats fed the high n-3 PUFA diet. In addition, binding of cytochalasin B indicated that the maximum binding to GLUT1 (Bmax) was reduced in deficient rats." (abstract, results, passage verified)
pubmedfull study (doi)
In a study by Chris McGlory and Stuart Phillips, preloading young women with 5 grams per day of omega-3 for 4 weeks before single-leg immobilization reduced disuse muscle atrophy by 50%.
"they gave these women for four weeks ahead of time, they gave them 5 grams of omega-3... and then they immobilized their leg... And what was found was that the the women that were given this omega-3 fatty acid supplement, it cut their disuse atrophy in half." (said at 0:41:40)
A randomized controlled trial led by Chris McGlory and Stuart Phillips evaluated 20 healthy young women who consumed either 5 g/day of omega-3 fatty acids or a control oil for 4 weeks prior to 2 weeks of unilateral leg immobilization. Following immobilization, the reduction in muscle volume was significantly lower in the omega-3 group compared to the control group (8% vs. 14% reduction, representing an attenuation of nearly half).
Meta-analyses show that supplementing older adults with 2 grams of omega-3 per day increases muscle mass and improves walking speed.
"So there's meta-analyses of studies that have found that if you supple if older adults supplement with 2 grams of omega-3 per day, they actually have higher muscle mass. They have improved walking speed." (said at 0:43:25)
A systematic review and meta-analysis of randomized controlled trials in older adults found that omega-3 fatty acid supplementation exceeding 2 g/day was associated with significant increases in muscle mass (gain of 0.67 kg; 95% CI: 0.16 to 1.18 kg) and improved walking speed, particularly in interventions lasting longer than 6 months (Huang et al., 2020). Other meta-analyses examining broader adult populations or lower doses have noted more variable results, but the specific dosage threshold (>2 g/day) in older populations is supported by meta-analytic subgroup findings.
The human gut contains approximately 1 gram of lipopolysaccharide (endotoxin) at any given moment.
"We have about a gram of this lipopolysaccharide in our guts at any given moment. It's a lot of it just sitting around." (said at 0:45:20)
The speaker's statement is consistent with established physiological estimates. The gastrointestinal tract harbors vast quantities of Gram-negative bacteria, and reviews of gut endotoxin dynamics estimate the total luminal pool of lipopolysaccharide (endotoxin) to be approximately 1 to 2 grams. Under healthy conditions, the intact intestinal epithelial barrier prevents this large reservoir of endotoxin from entering systemic circulation in significant amounts.
Omega-3 fatty acids suppress the postprandial release of lipopolysaccharide and endotoxin into the bloodstream following a meal.
"omega-3 actually decreases LPS release after a meal. So in this study here, there is a low-fat and a high-fat meal... after the meal, you can see it's suppressing the release of LPS and endotoxin into your bloodstream" (said at 0:51:00)
A randomized, controlled cross-over trial in 20 healthy adults examined the effect of different dietary fat compositions on postprandial serum endotoxin (lipopolysaccharide/LPS). Ingestion of a meal rich in omega-3 fatty acids (fish oil/DHA) significantly decreased postprandial serum endotoxin concentrations compared to baseline and saturated fat meals.
In animal studies, omega-3 fatty acids in the gut increase levels of intestinal alkaline phosphatase (IAP), which degrades LPS and kills LPS-producing bacteria.
"And it's increasing the level of a protein called IAP that degrades LPS in the gut. It degrades LPS in the gut. It also kills the bacteria that are producing LPS." (said at 0:52:10)
The host's claim accurately describes findings from animal and in vitro studies. Mouse models demonstrate that tissue omega-3 fatty acids increase the intestinal expression and secretion of intestinal alkaline phosphatase (IAP). IAP detoxifies (dephosphorylates) lipopolysaccharide (LPS) in the gut and retards the growth of LPS-producing Gram-negative bacteria such as Escherichia coli, reducing overall endotoxemia. Because the supporting evidence is currently limited to preclinical animal and cellular models, the certainty grade is very low.
- supports: Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation th… (Proceedings of the National Academy of Sciences of the United States of America 2010) · cited 187x in the literature
"One role recently attributed to ALPI is the detoxification of bacterial LPS. In our studies, RvE1-exposed epithelia detoxified LPS (assessed by attenuation of NF-kappaB signaling). Furthermore, in epithelial-bacterial interaction assays, we determined that ALPI retarded the growth of Escherichia coli." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty a… (Scientific reports 2015) · cited 357x in the literature
"Analysis of gut microbiota and fecal transfer revealed that elevated tissue omega-3 fatty acids enhance intestinal production and secretion of intestinal alkaline phosphatase (IAP), which induces changes in the gut bacteria composition resulting in decreased lipopolysaccharide production and gut permeability, and ultimately, reduced metabolic endotoxemia and inflammation." (abstract, results, passage verified)
pubmedfull study (doi)
In early research by Dr. Bill Harris, administering 30 grams of omega-3 per day to humans produced no negative effects over a short duration.
"Bill did studies gosh back in a long time ago, maybe the 1980s, giving people 30 grams of omega-3 a day and there was no negative effects." (said at 0:59:20)
In early metabolic ward studies conducted during the 1980s by Dr. William S. Harris and colleagues (such as Illingworth, Connor, and Harris), very large doses of omega-3 fatty acids (often 20 to 30 g/day of n-3 fatty acids from dietary salmon/fish oil, equivalent to roughly 70–100 g/day of fish oil) were administered to healthy volunteers and hyperlipidemic patients for short periods (typically 3 to 4 weeks). These high doses were well tolerated without serious adverse toxic effects, successfully lowering plasma triglycerides and VLDL. However, subsequent trials and reviews noted minor physiological changes such as mildly increased bleeding time and potential increases in LDL cholesterol in some dyslipidemic subgroups.
- context: Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic… (Atherosclerosis 1988) · cited 71x in the literature
"We conclude that dietary supplementation with fish oil results in a relatively minor degree of inhibition of platelet function in normal and hyperlipoproteinemic subjects, and a potentially adverse increase in LDL-cholesterol in type IV hyperlipoproteinemics." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients… (The New England journal of medicine 1985) · cited 856x in the literature
"We examined the effects of fish oil in 20 hypertriglyceridemic patients: 10 with Type IIb hyperlipidemia and 10 with Type V. These patients were put on three diets differing primarily in fatty acid composition and fat content." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Inhibition of low density lipoprotein synthesis by dietary omega-3 fatty acids in humans. (Arteriosclerosis (Dallas, Tex.) 1984) · cited 256x in the literature
"Seven healthy volunteers with normal plasma lipid levels consumed two metabolically controlled diets for a period of 4 weeks each. The control diet contained predominantly saturated and monounsaturated fatty acids, whereas the fish-oil diet contained 24 gm of omega-3 fatty acids per day." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 90% of the United States population does not consume sufficient omega-3 fatty acids from their diet.
"As I mentioned, 90% of the US population does not get enough omega-3 from their diet." (said at 0:33:29)
Nationally representative dietary survey data from the National Health and Nutrition Examination Survey (NHANES) support the claim. In an analysis of 24,621 participants from NHANES (2003–2008), more than 90% of the US population consumed less than the recommended 0.5 g/day of long-chain omega-3 fatty acids (EPA + DHA) from food sources, with a median dietary intake of only 0.11 g/day. Other NHANES analyses in specific demographics, such as women of childbearing age, similarly show that over 95% do not meet the recommended dietary guidelines for EPA and DHA.
Studies by Dr. William Harris show that supplementing with 1.5 to 2 grams per day of triglyceride-form omega-3 fatty acids increases the omega-3 index from a low baseline of 4% to a high target level of 8%.
"Bill Harris has done some studies also looking at what it takes to get someone from a low omega-3 index of 4% to a high omega-3 index. If they supplement, it seems as though if they're taking a triglyceride form, a little bit, maybe 1.5 to 2 grams a day. I like to say 2 grams a day is really to be safe, but 2 grams a day of omega-3 fatty acids seem to get people from a low to a high omega-3 index level." (said at 0:53:55)
A pooled dose-response modeling study led by Dr. William S. Harris and colleagues analyzed data from 1,422 individuals across 14 randomized intervention trials to quantify the effects of EPA and DHA supplementation on the Omega-3 Index (O3I). The model confirmed that baseline O3I, dose, and chemical formulation (triglyceride vs. ethyl ester) are the primary determinants of response. Across supplemented participants, a mean intake of approximately 1,983 mg/day (≈2 g/day) increased the average O3I from 4.9% to 8.1%. Because triglyceride-form formulations demonstrated greater bioavailability (raising the O3I by approximately 1 percentage point more than ethyl esters), doses of roughly 1.5 to 2.0 g/day of triglyceride-form omega-3 fatty acids reliably increase the O3I from a typical low baseline of 4% to the target level of 8%.
- supports: Predicting the effects of supplemental EPA and DHA on the omega-3 index. (The American journal of clinical nutrition 2019) · cited 94x in the literature
"Individuals supplemented with EPA + DHA (n = 846) took a mean ± SD of 1983 ± 1297 mg/d, and the placebo controls (n = 576) took none. The mean duration of supplementation was 13.6 ± 6.0 wk. The O3I increased from 4.9% ± 1.7% to 8.1% ± 2.7% in the supplemented individuals ( P < 0.0001). The final model included dose, baseline O3I, and chemical formulation type (EE or TG), and these explained 62% of the variance in response (P < 0.0001)... Gram for gram, TG-based supplements increased the O3I by about 1 percentage point more than EE products." (abstract, results, passage verified)
pubmedfull study (doi)
The human body absorbs significantly less omega-3 in ethyl ester form compared to the re-esterified triglyceride form.
"So when we metabolize, when we're taking an ethyl ester form, it's very different in terms of the enzymes that are cleaving things and how much we absorb. So we absorb far less of omega-3 in ethyl ester form than if someone were to then take that omega-3 that's been purified and then re-esterify it on a triglyceride backbone" (said at 1:01:36)
Clinical trial evidence demonstrates that omega-3 fatty acids in ethyl ester (EE) form have significantly lower bioavailability and absorption compared to re-esterified triglyceride (rTG) forms. In a randomized, controlled trial comparing different omega-3 preparations at equivalent doses of EPA and DHA, bioavailability from re-esterified triglycerides was 124% relative to natural fish oil, whereas bioavailability from ethyl esters was only 73%. This difference in absorption is mediated by differences in digestive enzymatic hydrolysis (such as pancreatic lipase activity) and micellar incorporation between the two chemical backbones.
- supports: Bioavailability of marine n-3 fatty acid formulations. (Prostaglandins, leukotrienes, and essential fatty acids 2010) · cited 252x in the literature
"Bioavailability of EPA+DHA from re-esterified triglycerides was superior (124%) compared with natural fish oil, whereas the bioavailability from ethyl esters was inferior (73%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-ester… (Prostaglandins, leukotrienes, and essential fatty acids 2011) · cited 48x in the literature
"Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability." (abstract, background, passage verified)
pubmedfull study (doi)
Microplastics in fish accumulate primarily in the gastrointestinal tract and intestines.
"I will say this about microplastics: they do accumulate in the intestines. And so eating like shellfish or fish that have the full intact—or like a sardine, like the full sardine—that's the worst thing you can do because if you're eating the intact digestive tract, that's where all the microplastics are accumulating." (said at 1:04:41)
Published ecological and toxicological studies consistently show that microplastics ingested by fish accumulate primarily in the gastrointestinal tract (GIT), with lower concentrations translocating to edible muscle tissues or gills. Because evisceration (gutting) removes the digestive tract and the highest concentration of microplastics, consuming whole small fish (such as sardines) or whole shellfish with intact digestive systems constitutes a primary route of dietary exposure to microplastics.
Omega-3 fatty acids protect against the toxic effects of mercury in maternal fish consumption during pregnancy.
"And it turns out that newer studies have come out since then that show that even women eating a lot of fish, in fact, the omega-3 fatty acids were protecting against the mercury toxicity." (said at 1:05:54)
Epidemiological cohort investigations (such as the Seychelles Child Development Study) and comprehensive risk-benefit assessments by the FDA and WHO/FAO demonstrate that the nutritional benefits of omega-3 polyunsaturated fatty acids (such as DHA) and other nutrients in fish counteract and modify the adverse neurodevelopmental effects of methylmercury exposure from maternal fish intake. Observational data indicate that higher maternal omega-3 status mitigates the negative associations of methylmercury on child neurodevelopmental measures, resulting in overall net positive developmental outcomes in children whose mothers regularly consumed fish during pregnancy.
Studies show that consuming farmed salmon raises blood omega-3 fatty acid levels just as effectively as wild salmon in some cases.
"And then some newer studies have come out showing that farm salmon raises omega-3 fatty acid levels just as good in some cases." (said at 1:07:55)
Clinical and nutritional studies confirm that consuming farmed salmon effectively increases human blood and plasma omega-3 fatty acid levels, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In randomized dietary crossover trials, consuming farmed Atlantic salmon twice weekly resulted in robust, dose-dependent increases in plasma phospholipid total omega-3 fatty acids and EPA. Furthermore, compositional analyses of commercial finfish fillets demonstrate that farmed salmon maintains substantial absolute concentrations of EPA and DHA per portion—often comparable to or exceeding certain wild species due to higher overall lipid content—supporting its ability to elevate circulating omega-3 levels just as effectively.
- supports: Dose-dependent consumption of farmed Atlantic salmon (Salmo salar) increases plasma phosph… (Journal of the Academy of Nutrition and Dietetics 2013) · cited 46x in the literature
"Eicosapentaenoic acid and total n-3 concentrations were increased (P<0.05) by all treatments in a dose-response manner, with total n-3 of 8.03% ± 0.26% and 9.21% ± 0.26% for 180- and 270-g doses, respectively." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fatty acid profiles of commercially available finfish fillets in the United States. (Lipids 2014) · cited 71x in the literature
"Of the top ten most popularly consumed seafoods in the US, finfish, including salmon species (717-1533 mg/100 g), Alaskan pollock (236 mg/100 g), tilapia (76 mg/100 g), channel catfish (44 mg/100 g), Atlantic cod (253 mg/100 g), and pangasius/swai (17 mg/100 g), exhibited a wide concentration range of EPA plus DHA." (abstract, results, passage verified)
pubmedfull study (doi)
Specialized pro-resolving mediators (SPMs) generated from omega-3 supplementation remain in circulation for 24 hours.
"because like there's studies showing that if you take an omega-3 fatty acid, these SPM molecules that are resolving inflammation stay in circulation for 24 hours." (said at 1:11:39)
Human pharmacokinetic and intervention studies demonstrate that oral supplementation with marine oil and omega-3 fatty acid formulations leads to time- and dose-dependent increases in circulating specialized pro-resolving mediators (SPMs, such as resolvins, protectins, and maresins) in peripheral blood, with elevated concentrations and downstream cellular reprogramming detected across a 24-hour observation period.
- supports: Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediat… (Circulation research 2020) · cited 157x in the literature
"Healthy volunteers were enrolled in a double-blinded, placebo-controlled, crossover study, and peripheral blood was collected at baseline, 2, 4, 6, and 24 hours post administration of placebo or one of 3 doses of an enriched marine oil supplement. Assessment of plasma SPM concentrations using lipid mediator profiling demonstrated a time- and dose-dependent increase in peripheral blood SPM concentration." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized … (International journal of molecular sciences 2023) · cited 13x in the literature
"This is an experimental pilot study in which ten healthy subjects were enrolled and received a single dose of 6 g of an oral SPM-enriched marine oil emulsion. Peripheral blood was collected at baseline, 3, 6, 9, 12, and 24 h post-administration. Temporal increases in plasma and serum SPM levels were found by using LC-MS/MS lipid profiling." (abstract, results, passage verified)
pubmedfull study (doi)
Wild Alaskan salmon has among the lowest mercury contamination levels of seafood.
"Very small 4-ounce piece wild Alaskan salmon. It does have the lowest amount of mercury contamination, but the microplastics are a concern." (said at 1:04:41)
The claim that wild salmon (including wild Alaskan salmon) has among the lowest mercury contamination levels of seafood is supported by food safety and environmental monitoring studies. Analysis of commercial finfish across the United States shows that salmon species consistently exhibit very low mean mercury concentrations (ranging from ~0.01 to 0.06 ppm / ppb), significantly lower than large predatory species like swordfish and king mackerel (which often exceed 1.0 ppm) as well as most other commercially available finfish species.
- supports: Mercury in fish available in supermarkets in Illinois: are there regional differences. (The Science of the total environment 2006) · cited 64x in the literature
"There were significant differences in mercury concentrations among the fish, ranging from a mean of 0.03 microg/g (ppm-wet weight) for salmon (Salmo spp.) to 1.41 ppm for swordfish (Xiphias gladius)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Mercury content in commercially available finfish in the United States. (Journal of food protection 2014) · cited 19x in the literature
"Of the top 10 most commonly consumed seafoods in the United States, all finfish species, including salmon species (13 to 62 ppb), Alaskan pollock (11 ppb), tilapia (16 ppb), channel catfish (1 ppb), Atlantic cod (82 ppb), and pangasius (swai) (2 ppb), had low total mercury concentrations." (abstract, results, passage verified)
pubmedfull study (doi)
Astaxanthin is a carotenoid pigment responsible for giving salmon its pink coloration.
"Astaxanthin is a carotenoid that gives salmon its pink color and it's also very beneficial as well." (said at 1:07:23)
Astaxanthin is well established as a lipophilic keto-carotenoid pigment responsible for the characteristic pink-to-red flesh pigmentation of salmonids, where it is absorbed from the diet and deposited into muscle tissue. It is also widely studied for its potent antioxidant and biological properties.
- supports: Molecular Mechanism Involved in Carotenoid Metabolism in Post-Smolt Atlantic Salmon: Astax… (Marine biotechnology (New York, N.Y.) 2021) · cited 29x in the literature
"A better understanding of carotenoid dynamics (transport, absorption, metabolism, and deposition) is essential to develop a better strategy to improve astaxanthin (Ax) retention in muscle of Atlantic salmon." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Pharmaceutical and nutraceutical potential of natural bioactive pigment: astaxanthin. (Natural products and bioprospecting 2022) · cited 101x in the literature
"Astaxanthin (3,3'-dihydroxy-β,β-carotene-4,4'-dione) is an orange-red, lipophilic keto-carotenoid pigment. It is majorly found in marine ecosystems particularly in aquatic animals such as salmon, shrimp, trout, krill, crayfish, and so on." (abstract, description, passage verified)
pubmedfull study (doi) - supports: Recent progress in practical applications of a potential carotenoid astaxanthin in aquacul… (Fish physiology and biochemistry 2024) · cited 145x in the literature
"Astaxanthin is the main natural C40 carotenoid used worldwide in the aquaculture industry. It normally occurs in red yeast Phaffia rhodozyma and green alga Haematococcus pluvialis and a variety of aquatic sea creatures, such as trout, salmon, and shrimp." (abstract, background, passage verified)
pubmedfull study (doi)
Developing fetuses are significantly more sensitive to mercury toxicity than adults.
"...because if a developing fetus, which is very, very sensitive to mercury, way more sensitive than we are as adults, if they're okay and protected by the omega-3 fatty acids, I feel a lot better about eating some sardines and getting some mercury in." (said at 1:09:20)
The claim that developing fetuses are significantly more sensitive to mercury toxicity than adults is well-supported by extensive epidemiological and toxicological research. Methylmercury readily crosses the placenta, and the developing fetal brain undergoes critical neurodevelopmental processes (such as cell proliferation, migration, and differentiation) that make it especially vulnerable to damage at lower exposure thresholds than adult brains (Harada, 1996, PMID: 9182044; Landrigan et al., 2007, PMID: 18074303). Animal models similarly confirm higher brain methylmercury uptake and greater susceptibility in fetuses and neonates compared to adults (Ishitobi et al., 2018, PMID: 30005196; Farina et al., 2021, PMID: 34299140).
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.